|
Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 0,6170 EUR | -3,59% |
|
-13,51% | -53,08% |
| 13/07 | AB Science staakt drie klinische studies met masitinib | MT |
| 10/07 | AB Science rationaliseert portefeuille en focust op twee moleculen |  |
Belangrijkste concurrenten
Toevoegen aan een lijst 0 geselecteerde | Verschil (%) | Varia. 5d. | Evolutie 1 maand | Evolutie 3 maanden | Var. 1 jan | Varia. 1j. | Varia. 3j. | Varia. 5j. | Varia. 10j. | Kap.($) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 | +3,54% | +2,27% | +11,07% | +10,79% | +21,52% | +55,18% | +21,17% | +63,95% | +116,73% | 305 mld. | |
| -1,53% | -1,18% | +4,47% | +19,80% | +12,52% | +24,90% | -7,29% | -19,21% | +45,56% | 69,67 mld. | |
| +1,25% | -1,92% | +10,73% | +15,71% | +14,58% | +32,93% | +91,48% | +83,38% | +757,73% | 8,99 mld. | |
| +0,23% | -1,27% | +10,76% | +4,92% | +4,69% | +6,72% | -0,25% | -29,64% | +48,21% | 8,52 mld. | |
| -3,05% | +4,98% | +22,01% | +42,43% | +39,41% | +10,85% | +28,13% | -31,69% | - | 4,17 mld. | |
| +1,53% | -3,29% | -11,97% | -24,88% | -36,28% | -19,72% | +3,79% | -38,21% | - | 4,11 mld. | |
| +1,87% | +2,46% | -10,27% | -27,16% | -37,01% | -37,23% | +24,94% | +31,77% | +64,21% | 3,48 mld. | |
| +0,26% | -1,91% | +9,73% | -2,84% | -3,78% | +42,66% | +62,49% | +80,79% | +130,24% | 2,77 mld. | |
| -0,81% | +8,11% | +13,29% | -8,83% | -11,71% | +14,84% | -16,29% | +48,08% | - | 2,28 mld. | |
| -3,46% | +16,30% | +20,31% | -1,41% | +5,00% | -14,23% | +40,22% | -27,79% | - | 2,08 mld. | |
| +1,54% | +6,09% | +7,83% | -7,70% | -8,61% | -17,59% | -15,17% | -4,65% | -39,16% | 1,8 mld. | |
| -.--% | -.--% | - | - | - | - | - | - | - | 1,64 mld. | |
| -0,32% | +0,40% | +41,10% | +22,15% | +39,61% | +42,94% | +133,33% | +31,46% | - | 1,4 mld. | |
| +1,34% | +6,67% | +8,32% | -23,12% | -6,40% | -34,52% | -22,77% | - | - | 1,31 mld. | |
| +0,60% | +0,72% | +6,20% | -12,88% | -9,78% | +1,70% | +43,66% | +85,29% | +86,94% | 1,07 mld. | |
| -3,82% | -3,99% | -16,95% | -42,87% | -41,29% | +42,78% | +34,43% | +15,92% | +400,63% | 1,12 mld. | |
| -0,90% | +2,57% | +18,36% | +56,73% | +126,43% | +175,67% | +1.180,60% | +603,86% | - | 1,05 mld. | |
| +1,45% | -1,61% | -5,08% | -20,66% | -17,04% | +69,73% | -8,55% | -69,08% | -95,39% | 935 mln. | |
| +1,20% | +5,00% | +9,09% | -11,58% | -9,35% | -31,34% | -5,97% | -50,30% | -64,76% | 950 mln. | |
| Gemiddelde | +0,05% | -0,27% | +8,28% | -0,63% | +4,58% | +20,35% | +88,22% | +45,53% | +131,91% | 22,25 mld. | |
| Gewogen gemiddelde per kap. | +2,34% | -4,58% | +9,69% | +11,31% | +17,95% | +45,47% | +20,57% | +46,34% | +116,02% |
Kies MarketScreener Kies jouw editie
Alle financiële informatie op nationaal niveau
